Stock AVTE AEROVATE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Aerovate Therapeutics, Inc.

Equities

AVTE

US0080641071

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
21.75 USD +0.83% Intraday chart for Aerovate Therapeutics, Inc. -1.36% -3.89%
Apr. 12 Aerovate Therapeutics Insider Sold Shares Worth $334,478, According to a Recent SEC Filing MT
Apr. 04 Aerovate Therapeutics Insider Sold Shares Worth $300,033, According to a Recent SEC Filing MT

Evolution of the average Target Price on Aerovate Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

83800c6b4eaf623d74114ee8b.OHHMDYPylp7T7-KuuNeNKvOrjtyXEU6wW_HAwpqIPxw.fQanaLueyfyGiYDf_4D_ab3J26nTVDrvbJf48djAc25iJoNU5bzm7LuJtw~9a13714caced3035fe28d770fef813fe

Analyst Recommendations on Aerovate Therapeutics, Inc.

Aerovate Therapeutics Insider Sold Shares Worth $334,478, According to a Recent SEC Filing MT
Aerovate Therapeutics Insider Sold Shares Worth $300,033, According to a Recent SEC Filing MT
Aerovate Therapeutics Insider Sold Shares Worth $908,046, According to a Recent SEC Filing MT
Wedbush Adjusts Aerovate Therapeutics Price Target to $48 From $50, Maintains Outperform Rating MT
Wedbush Lowers Aerovate Therapeutics' Price Target to $50 From $54, Keeps Outperform Rating MT
Guggenheim Initiates Aerovate Therapeutics at Buy With $36 Price Target MT
Wedbush Raises Aerovate Therapeutics' PT to $54 From $27 on Increased Confidence in Inhaled TKIs, AV-10; Keeps Outperform Rating MT
BTIG Upgrades Aerovate Therapeutics to Buy From Neutral, Price Target Is $27 MT
Wedbush Analyst Assumes Coverage on Aerovate Therapeutics at Outperform With $27 Price Target, Down From $32 MT
Wedbush Analyst Assumes Coverage on Aerovate Therapeutics at $27, Down From $32; Outperform Rating Kept MT
Wedbush Lifts Price Target on Aerovate Therapeutics to $32 From $23, Keeps Outperform Rating MT
BTIG Downgrades Aerovate Therapeutics to Neutral From Buy MT
BTIG Initiates Aerovate Therapeutics at Buy With $24 Price Target MT
AEROVATE THERAPEUTICS : Evercore ISI Group Initiates Aerovate Therapeutics at Outperform Rating With $30 Price Target MT
AEROVATE THERAPEUTICS : Jefferies Starts Aerovate Therapeutics at Buy With $21 Price Target MT
AEROVATE THERAPEUTICS : Cowen Initiates Coverage on Aerovate Therapeutics With Outperform Rating MT
AEROVATE THERAPEUTICS : Wedbush Starts Aerovate Therapeutics at Outperform With $23 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
21.75 USD
Average target price
44.67 USD
Spread / Average Target
+105.36%
High Price Target
65 USD
Spread / Highest target
+198.85%
Low Price Target
27 USD
Spread / Lowest Target
+24.14%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Aerovate Therapeutics, Inc.

Wedbush
Guggenheim
BTIG
Jefferies & Co.
Cowen
Evercore ISI

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. AVTE Stock
  4. Consensus Aerovate Therapeutics, Inc.